Ixekizumab
Identification
- Summary
Ixekizumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
- Brand Names
- Taltz
- Generic Name
- Ixekizumab
- DrugBank Accession Number
- DB11569
- Background
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.
Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- C6492H10012N1728O2028S46
- Protein Average Weight
- 146158.0 Da
- Sequences
>Heavy Chain Sequence QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDY NQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSA STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGN VFSCSVMHEALHNHYTQKSLSLSLG
>Light Chain Sequence DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRF IGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Download FASTA Format- Synonyms
- Ixekizumab
- External IDs
- LY 2439821
- LY-2439821
- LY2439821
Pharmacology
- Indication
Ixekizumab is indicated for the treatment of patients aged six years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is also indicated in adult patients with active psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis with objective signs of inflammation.4
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.
Target Actions Organism AInterleukin-17A antibodyHumans - Absorption
Following a single subcutaneous dose of 160 mg in subjects with plaque psoriasis, ixekizumab reached peak mean (±SD) serum concentrations (Cmax) of 16.2 ±6.6 mcg/mL by approximately 4 days post dose.
- Volume of distribution
The mean (geometric CV%) volume of distribution at steady-state was 7.11 L (29%) in subjects with plaque psoriasis.
- Protein binding
Not Available
- Metabolism
The metabolic pathway of ixekizumab has not been characterized. As a humanized IgG4 monoclonal antibody ixekizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.
- Route of elimination
Not Available
- Half-life
13 days
- Clearance
0.39 L/day
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
The most common adverse reactions associated with Ixekizumab treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Ixekizumab. Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Ixekizumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ixekizumab. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ixekizumab. Aducanumab The risk or severity of adverse effects can be increased when Ixekizumab is combined with Aducanumab. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ixekizumab. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Ixekizumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixekizumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Ixekizumab. Allogeneic processed thymus tissue The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Ixekizumab. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Taltz Solution 80 mg / mL Subcutaneous Eli Lilly & Co. Ltd. 2016-08-11 Not applicable Canada Taltz Injection, solution 80 mg Subcutaneous Eli Lilly And Company (Ireland) Limited 2016-09-08 Not applicable EU Taltz Injection, solution 80 mg/1mL Subcutaneous Eli Lilly and Company 2016-03-22 Not applicable US Taltz Injection, solution 80 mg Subcutaneous Eli Lilly And Company (Ireland) Limited 2016-09-08 Not applicable EU Taltz Solution 80 mg / mL Subcutaneous Eli Lilly & Co. Ltd. 2016-08-11 Not applicable Canada Taltz Injection, solution 80 mg Subcutaneous Eli Lilly And Company (Ireland) Limited 2016-09-08 Not applicable EU Taltz Injection, solution 80 mg Subcutaneous Eli Lilly And Company (Ireland) Limited 2016-09-08 Not applicable EU Taltz Injection, solution 80 mg/1mL Subcutaneous Eli Lilly and Company 2016-03-22 Not applicable US Taltz Injection, solution 80 mg Subcutaneous Eli Lilly And Company (Ireland) Limited 2016-09-08 Not applicable EU Taltz Injection, solution 80 mg Subcutaneous Eli Lilly And Company (Ireland) Limited 2016-09-08 Not applicable EU
Categories
- ATC Codes
- L04AC13 — Ixekizumab
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antibodies
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic and Immunomodulating Agents
- Blood Proteins
- Dermatologicals
- Globulins
- Immunoglobulins
- Immunoproteins
- Immunosuppressive Agents
- Interleukin Inhibitors
- Interleukin-17
- Interleukin-17A Antagonist
- Misc. Skin and Mucous Membrane Agents
- Proteins
- Serum Globulins
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- BTY153760O
- CAS number
- 1143503-69-8
References
- General References
- Dyring-Andersen B, Skov L, Zachariae C: Ixekizumab for treatment of psoriasis. Expert Rev Clin Immunol. 2015 Apr;11(4):435-42. doi: 10.1586/1744666X.2015.1023295. Epub 2015 Mar 8. [Article]
- Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J: LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010 Apr;62(4):929-39. doi: 10.1002/art.27334. [Article]
- Bush KA, Farmer KM, Walker JS, Kirkham BW: Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002 Mar;46(3):802-5. [Article]
- FDA Approved Drug Products: TALTZ (ixekizumab) injection [Link]
- External Links
- KEGG Drug
- D10071
- PubChem Substance
- 347911203
- 1745099
- ChEMBL
- CHEMBL1743034
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Ixekizumab
- FDA label
- Download (6.58 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Erythrodermic psoriasis / Generalized Pustular Psoriasis (GPP) 1 4 Completed Treatment Psoriasis Vulgaris (Plaque Psoriasis) 1 4 Completed Treatment Psoriatic Arthritis 1 4 Recruiting Other Psoriasis Vulgaris (Plaque Psoriasis) 1 4 Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) / Psoriatic Arthritis / Rheumatoid Arthritis / Spondylarthritis 1 4 Recruiting Treatment Anterior Uveitis (AU) / Panuveitis / Posterior Uveitis / Uveitis, Intermediate 1 4 Recruiting Treatment Psoriasis Vulgaris (Plaque Psoriasis) / Psoriatic Arthritis 1 4 Recruiting Treatment Psoriasis / Psoriasis Vulgaris (Plaque Psoriasis) 1 3 Completed Treatment Axial Spondyloarthritis (AxSpA) 2 3 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Injection, solution 80 mg/1ml Injection, solution Parenteral; Subcutaneous 80 MG Injection, solution Subcutaneous 80 mg Injection, solution Subcutaneous 80 mg/1mL Solution Subcutaneous 80 mg / mL Solution Subcutaneous 80 mg Solution Subcutaneous 80.000 mg Injection, solution Subcutaneous Injection, solution Subcutaneous 80 mg/ml Injection, solution 80 mg/ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets

- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antibody
- General Function
- Cytokine receptor binding
- Specific Function
- Induces stromal cells to produce proinflammatory and hematopoietic cytokines. Enhances the surface expression of ICAM1/intracellular adhesion molecule 1 in fibroblasts.
- Gene Name
- IL17A
- Uniprot ID
- Q16552
- Uniprot Name
- Interleukin-17A
- Molecular Weight
- 17503.92 Da
Drug created at April 06, 2016 15:41 / Updated at June 03, 2022 07:24